A year after Bristol-Myers Squibb declined an option to acquire it in 2018, Promedior has found another buyer in Roche which has agreed to pay up to US$1.4 B for the company. With the deal, Roche gains the full rights to Promedior's entire portfolio of molecules for fibrotic diseases, most notably PRM-151 which is in clinical development for the treatment of idiopathic pulmonary fibrosis, myelofibrosis, non-alcoholic steatohepatitis (NASH) and fibrotic kidney disease.